Anti-biofilm activity of bacteriophage-antibiotic combinations against MRSA
噬菌体-抗生素组合对 MRSA 的抗生物膜活性
基本信息
- 批准号:10285430
- 负责人:
- 金额:$ 19.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-10 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdjuvantAgeAnti-Bacterial AgentsAntibiotic ResistanceAntibiotic TherapyAntibioticsBacteremiaBacteriaBacterial Antibiotic ResistanceBacteriophagesCatheter-related bloodstream infectionCathetersCefazolinCellsCenters for Disease Control and Prevention (U.S.)ClinicalCombined AntibioticsCombined Modality TherapyCytolysisDaptomycinDataDevelopmentDirect CostsDoseDrug KineticsDrug resistanceExhibitsFailureFrequenciesFutureGenerationsGenotypeGenus staphylococcusGoalsGrowthHealthcare SystemsHourImmune systemIn VitroInfectionInvestigationLaboratoriesLeadLifeLyticMeasuresMedical DeviceMetabolicMicrobial BiofilmsModelingMonobactamsMulti-Drug ResistanceMultiple Bacterial Drug ResistanceNosocomial InfectionsOutcomePatient CarePenetrationPharmacodynamicsPhenotypePredispositionPreventionProductionPublic HealthRegimenReportingResearchResistanceResistance developmentRifampinSecondary toSepsisStaphylococcus aureusSupplementationTechniquesTestingTherapeuticTimeTreatment FailureVancomycinVenousVirionWorkalternative treatmentantimicrobialattributable mortalitybacterial resistancebactericidebasecatheter related infectioncosteffective therapyefficacy evaluationemerging antibiotic resistanceexperimental studyfitnessimprovedin vitro activitymethicillin resistant Staphylococcus aureusmortalitymulti-drug resistant pathogennovelpathogenpharmacodynamic modelpreventresponsestandard of caresynergismtreatment optimization
项目摘要
Summary/Abstract
Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are problematic
because of the high associated treatment failures and elevated mortality rates. Staphylococci
including MRSA are the major cause of medical device infections (MDIs) due to their strong
capability to form biofilms. These bacterial biofilms resist host immune system and lead to
antibiotic failure due to limited antibiotic penetration, bacterial tolerance and development of
antibiotic resistance. Vancomycin is the recommended therapy for MRSA MDIs and daptomycin
is the primary antibiotic alternative to vancomycin for these infections; however, the development
of daptomycin resistance especially post vancomycin therapy has been reported with increasing
frequency. Although combination therapy of vancomycin or daptomycin with beta-lactam
antibiotics such as ceftaroline have demonstrated improved activity in vitro, these combinations
have not shown significant enhancements in MDIs caused by Staphylococci. Therefore, due to
the lack of effective MDI treatments, novel antibacterial options are critically needed. Obligately
lytic bacteriophages (phages) infect bacteria, replicate within the cell, lyse the cell to release their
progeny and reinitiate the infection cycle. These phages eradicate both antibiotic susceptible and
resistant bacteria in planktonic and biofilm forms. The combination of phage and antibiotics have
shown to re-sensitize previously multi-drug resistant bacteria to antibiotics. Synergistic and
antagonistic interactions in phage-antibiotic combinations are highly dependent on the
mechanism of bacterial inhibition of the antibiotic paired to the phage, bacterial host state (biofilm
versus planktonic) and bacterial growth age. Here we are offering a systematic investigation of
phage antibiotic combination using various standard of care antibiotics (SOC) to examine the
aforementioned parameters. The proposed research is significant especially due to lack of
information regarding the use of phage with SOC antibiotics against biofilm embedded MRSA
strains. Our central hypothesis is that the combination of phage-antibiotic will reduce the
vancomycin and daptomycin exposures required for efficacy against biofilm embedded MRSA
and further prevent the emergence of antibiotic resistance. We will test our central hypothesis by
first evaluating susceptibility of biofilm embedded MRSA to various phage-antibiotic
combinations and then performing in vitro two-compartment PK/PD biofilm models with
humanized pharmacokinetics to optimize novel phage-antibiotic combination therapies. We
expect that through optimizing therapy of MRSA-biofilm infections, we will improve patient care
and prolong the useful life of vancomycin and daptomycin for the management of MRSA MDIs.
摘要/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Joseph Rybak其他文献
Michael Joseph Rybak的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Joseph Rybak', 18)}}的其他基金
Anti-biofilm activity of bacteriophage-antibiotic combinations against MRSA
噬菌体-抗生素组合对 MRSA 的抗生物膜活性
- 批准号:
10426350 - 财政年份:2021
- 资助金额:
$ 19.25万 - 项目类别:
A Pharmacologic Approach to Prevent Daptomycin Resistance in VRE
预防 VRE 达托霉素耐药的药理学方法
- 批准号:
9009253 - 财政年份:2015
- 资助金额:
$ 19.25万 - 项目类别:
A Pharmacologic Approach to Prevent Daptomycin Resistance in VRE
预防 VRE 达托霉素耐药的药理学方法
- 批准号:
9193057 - 财政年份:2015
- 资助金额:
$ 19.25万 - 项目类别:
Impact of daptomycin dose exposure on biofilm embedded Enterococci resistance
达托霉素剂量暴露对生物膜嵌入肠球菌耐药性的影响
- 批准号:
8620019 - 财政年份:2014
- 资助金额:
$ 19.25万 - 项目类别:
Impact of daptomycin dose exposure on biofilm embedded Enterococci resistance
达托霉素剂量暴露对生物膜嵌入肠球菌耐药性的影响
- 批准号:
8898002 - 财政年份:2014
- 资助金额:
$ 19.25万 - 项目类别:
Impact of Daptomycin Dose Exposure on Enterococci and Characterization of Resista
达托霉素剂量暴露对肠球菌的影响和耐药性的表征
- 批准号:
8029807 - 财政年份:2011
- 资助金额:
$ 19.25万 - 项目类别:
Impact of Daptomycin Dose Exposure on Enterococci and Characterization of Resista
达托霉素剂量暴露对肠球菌的影响和耐药性的表征
- 批准号:
8339442 - 财政年份:2011
- 资助金额:
$ 19.25万 - 项目类别:
相似海外基金
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10458553 - 财政年份:2021
- 资助金额:
$ 19.25万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10220588 - 财政年份:2021
- 资助金额:
$ 19.25万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10620718 - 财政年份:2021
- 资助金额:
$ 19.25万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10415762 - 财政年份:2021
- 资助金额:
$ 19.25万 - 项目类别:
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
剖析年龄特异性佐剂体外和体内协同作用的机制
- 批准号:
9108575 - 财政年份:2016
- 资助金额:
$ 19.25万 - 项目类别:
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
CoVPN 3005:两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性 - LC 3
- 批准号:
10570739 - 财政年份:2006
- 资助金额:
$ 19.25万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10686595 - 财政年份:2006
- 资助金额:
$ 19.25万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - 两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成年人的功效、免疫原性和安全性
- 批准号:
10581414 - 财政年份:2006
- 资助金额:
$ 19.25万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10579557 - 财政年份:2006
- 资助金额:
$ 19.25万 - 项目类别: